US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Results from the heart preservation study presented on ISHLT

At ISHLT, the good results from the first six heart transplant patients from the study at Lund University Hospital were presented. The heart preservation technology used in the study is developed by Professor Stig Steen. Previous published preclinical experiments have demonstrated that the method has the potential to extend the time a heart can be preserved outside the body (Ex Vivo).ISHLT (The International Society for Heart and Lung Transplantation) was held at the beginning of April, and at this conference, Professor Johan Nilsson presented the good results from the first six heart

Professor Stig Steen’s heart preservation technology required for successful transplantation from pigs to baboons

According to an article published earlier this week in the scientific journal Nature, use of Professor Stig Steen’s heart preservation technology is required for successful xenotransplantation from pigs to baboons. This is an important step for XVIVO as well, as XVIVO’s heart preservation products are based on this technology and XVIVO owns all commercial rights to the technology.The well-reputed scientific journal Nature published earlier this week an article from Munich University Hospital which describes, the long-term survival of baboons that had received a heart transplant from

First clinical heart transplant performed using Stig Steen’s new method

Through its collaboration agreement with Igelösa, XVIVO Perfusion has the commercial rights to Professor Stig Steen’s research on heart transplants. The research has resulted in a method in connection with heart transplants that makes it possible to transport and preserve the heart from a donor in a more optimized way. Previous animal experiments have demonstrated that the method has the potential to extend the time a heart can be preserved outside the body (Ex Vivo). The first clinical heart transplant using the new method has now been performed at Skåne University Hospital.Approximately 6,

XVIVO Perfusion Interim report January – June 2016

ACQUISITION OF VIVOLINE STRENGTHENS XVIVO’S PRODUCT AND R&D PORTFOLIOSECOND QUARTER 2016 (APR – JUN) • Net sales in the quarter amounted to SEK 34.5 (29.1) million, corresponding to an increase of 18 percent. Net sales of non-Durable goods* in the quarter amounted to SEK 29.8 (27.4) million, corresponding to an increase of 9 percent in SEK and 11 percent in local currency.• Operating income before depreciation and amortization (EBITDA) excluding one-time expenses increased by 51 percent and amounted to SEK 6.9 (4.6) million, corresponding to an EBITDA margin of 20 percent. One-time

Extension of the acceptance period of XVIVO Perfusion’s public offer on Vivoline Medical has ended

The Offer is not made, and this press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South Africa or the U.S or in any other country where making of the Offer, distribution of this press release or acceptance of the Offer would be contrary to applicable laws or rules or would require further offering documentation or registration or any other measures in addition to what is required by Swedish law.  XVIVO Perfusion AB (“XVIVO Perfusion”) announced on 18 April 2016 a recommended public offer to the holders of shares (“

Decision of the Arbitration Board regarding XVIVO Perfusion’s rights to the Vivoline patents

The Arbitration Board has announced its decision regarding which agreement rights XVIVO has in relation to three patents Stig Steen/Igelösa transferred to Vivoline. The decision means that the Arbitration Board does not consider that XVIVO has a right to the low potassium dextran (LPD) solutions containing calcium, pursuant to the improvement clause in the current agreement that the company has with Igelösa.  The decision states that the question was complex, which can also be understood by the fact that the outcome was negative even though XVIVO’s case had found support among legal and

XVIVO launches the XPS™ system in Europe

XVIVO Perfusion is launching its newly developed appliance for lung perfusion, XPS™ (Xvivo Perfusion System), in Europe on the basis of good clinical results and great interest from clinics. Since 2009, XVIVO Perfusion AB (publ) has developed and sought patents for a complete system for the evaluation of lungs (EVLP) so as to facilitate use of STEEN Solution™. XPS™ also contains a ventilator and will be marketed with accompanying specially adapted disposable products. By increasing the number of lungs available for transplantation, more patients with severe lung disease can be given a

XVIVO Perfusion files lawsuit against Vivoline

XVIVO Perfusion is suing Vivoline to safeguard XVIVO Perfusion’s exclusive rights to Vivoline’s patents for three products invented by Professor Stig Steen.XVIVO Perfusion AB (publ) has today initiated legal proceedings against Vivoline Medical in order to safeguard the exclusive global unlimited rights that XVIVO Perfusion AB (publ) has to certain media developed by Professor Stig Steen for the evaluation and preservation of organs in connection with transplantation. XVIVO Perfusion’s own product STEEN Solution™ is not part of the dispute and is protected by a patent which has been

Clarification of XVIVO Perfusion’s rights to Professor Stig Steen’s media for the preservation and evaluation of organs

Due to the insufficient information that Vivoline Medical has distributed in a Memorandum (including supplementary information that was recently published) ahead of its planned new share issue and listing on AktieTorget, XVIVO Perfusion feels obliged to provide information on the exclusive global unlimited rights that XVIVO Perfusion has to certain media developed by Professor Stig Steen and Vivoline Medical for the evaluation and preservation of organs in connection with transplantation. Pursuant to the current agreement with Professor Stig Steen and Igelösa Life Science AB, XVIVO

There are no items matching the current filter
There are no more items matching the current filter
Back to top